Company news

Agios Pharmaceuticals, Inc. news in 2026

Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

October 30, 2026

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8: 00 a.m. ET

October 8, 2026

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

July 21, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

July 7, 2026

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8: 00 a.m. ET

June 29, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

June 13, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

June 1, 2026

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

May 29, 2026

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 22, 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

May 12, 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

April 29, 2026

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8: 00 a.m. ET

April 6, 2026

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

March 30, 2026

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

March 1, 2026

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 12, 2026

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8: 00 a.m. ET

January 25, 2026

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

January 11, 2026

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

January 4, 2026

Calls in 2026

Decks in 2026